Amedex Biotherapeutics moves listing to Nasdaq Capital Market

Amedex Biotherapeutics (LABT.O) shifted its stock listing to the Nasdaq Capital Market on April 23, 2026, following a $7.5 million private placement of Series C Convertible Preferred Stock. The listing simplifies its capital structure, with earlier preferred stock and convertible notes converted into common stock. Shareholders are to vote on Sept. 22 on increasing authorized common shares and granting authority for a reverse stock split if needed for Nasdaq.